Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
RESEARCH TOOLSreports
Holding JANX?
Track your performance easily
JANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.79 - $65.60
Previous Close$46.5
Volume797.15K
Average Volume (3M)611.30K
Market Cap
$2.44B
Enterprise Value$1.81B
Total Cash (Recent Filing)$658.03M
Total Debt (Recent Filing)$23.43M
Price to Earnings (P/E)―
Beta2.82
Next Earnings
Mar 07, 2025EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding52,482,020
10 Day Avg. Volume614,145
30 Day Avg. Volume611,300
Standard Deviation0.78
R-Squared0.05
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)3.92
Price to Sales (P/S)197.11
Price to Cash Flow (P/CF)-288.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue138.39
Enterprise Value/Gross Profit223.41
Enterprise Value/Ebitda-27.18
Forecast
1Y Price Target
$71.88Price Target Upside42.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Janux Therapeutics Inc News
PremiumCompany Announcements
Janux Therapeutics’ Q3 Report: Financials and Progress
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageJANX007 showed high PSA50 rates with no G3+ CRS, suggesting it could be a best-in-class PSMA agent and a leading therapy for late-stage mCRPC.
Drug Efficacy And SafetyJANX007 is expected to have a better drug profile with higher efficacy, better safety, and not limited by dose-limiting toxicities, translating to longer durability.
Financial PerformanceThe price target is raised from $62 to $82 based on the conviction of positive data in the upcoming 007 readout and updated model assumptions.
Bears Say
Clinical Trial ResultsAmgen's STEAP1 asset showed markedly reduced efficacy and poorer safety at ESMO.
Financial PerformanceThe company reported total revenues of approximately $0.44M and a net loss of $0.51 per share, compared to the consensus estimates of total revenues of $0.77M and a net loss of $0.35 per share.
Safety Concerns≥Grade 3 ILD events are one of the main concerns with J&J's data.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $7.79 and its highest was $65.60 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Currently, no data Available
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is Mar 07, 2025 which is in 104 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Nov 06, 2024. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.183.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -$0.41.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 52,482,020 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went down -1.239%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Among the largest hedge funds holding Janux Therapeutics Inc’s share is RA Capital Management. It holds Janux Therapeutics Inc’s shares valued at 416M.
---
Janux Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.88 (42.87% Upside)
$71.88 (42.87% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $72.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
434.48%
12-Months-Change
Fundamentals
Return on Equity
-12.05%
Trailing 12-Months
Asset Growth
79.66%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
---
JANX Stock 12 Month Forecast
Average Price Target
$71.88
▲(42.87% Upside)
Technical Analysis
Nurix Therapeutics
―
RAPT Therapeutics
―
Bicycle Therapeutics
―
Fulcrum Therapeutics
―
Best Analysts Covering JANX
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+92.36%
reiterated a buy rating 4 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +92.36% per trade.
---